image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 1.1
2.8 %
$ 409 M
Market Cap
-2.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LAB stock under the worst case scenario is HIDDEN Compared to the current market price of 1.1 USD, Standard BioTools Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LAB stock under the base case scenario is HIDDEN Compared to the current market price of 1.1 USD, Standard BioTools Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one LAB stock under the best case scenario is HIDDEN Compared to the current market price of 1.1 USD, Standard BioTools Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LAB

image
$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
174 M REVENUE
64.03%
-175 M OPERATING INCOME
-128.77%
-139 M NET INCOME
-86.03%
-143 M OPERATING CASH FLOW
-231.40%
363 M INVESTING CASH FLOW
1694.60%
-103 M FINANCING CASH FLOW
-1407.06%
46.7 M REVENUE
3.89%
-62.8 M OPERATING INCOME
-97.98%
-34.1 M NET INCOME
-26.48%
-14.1 M OPERATING CASH FLOW
49.55%
25.7 M INVESTING CASH FLOW
183.30%
-54.5 M FINANCING CASH FLOW
-2725900.00%
Balance Sheet Standard BioTools Inc.
image
Current Assets 376 M
Cash & Short-Term Investments 293 M
Receivables 33.6 M
Other Current Assets 49.4 M
Non-Current Assets 236 M
Long-Term Investments 0
PP&E 71.4 M
Other Non-Current Assets 165 M
47.83 %5.49 %8.07 %11.66 %26.96 %Total Assets$612.3m
Current Liabilities 65.9 M
Accounts Payable 12.3 M
Short-Term Debt 12.5 M
Other Current Liabilities 41.2 M
Non-Current Liabilities 74.7 M
Long-Term Debt 26.8 M
Other Non-Current Liabilities 48 M
8.73 %8.86 %29.27 %19.04 %34.11 %Total Liabilities$140.6m
EFFICIENCY
Earnings Waterfall Standard BioTools Inc.
image
Revenue 174 M
Cost Of Revenue 90.2 M
Gross Profit 84.3 M
Operating Expenses 259 M
Operating Income -175 M
Other Expenses -36.4 M
Net Income -139 M
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)174m(90m)84m(259m)(175m)36m(139m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
48.31% GROSS MARGIN
48.31%
-100.46% OPERATING MARGIN
-100.46%
-79.62% NET MARGIN
-79.62%
-29.44% ROE
-29.44%
-22.68% ROA
-22.68%
-31.48% ROIC
-31.48%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Standard BioTools Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -139 M
Depreciation & Amortization 4.35 M
Capital Expenditures -8.36 M
Stock-Based Compensation 31.7 M
Change in Working Capital 0
Others -56 M
Free Cash Flow -152 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Standard BioTools Inc.
image
LAB has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Standard BioTools Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
5.13 M USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
12.6 M USD 1
6-9 MONTHS
5.26 M USD 1
9-12 MONTHS
7. News
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: globenewswire.com - 1 month ago
Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript Standard BioTools Inc. (NASDAQ:LAB ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Kyle Boucher - TD Cowen Paul Knight - KeyBanc Operator Good day, everyone, and welcome to Standard BioTools' Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this conference is being recorded. seekingalpha.com - 1 month ago
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. globenewswire.com - 1 month ago
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. globenewswire.com - 2 months ago
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. globenewswire.com - 3 months ago
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. globenewswire.com - 4 months ago
Standard BioTools Appoints Alex Kim as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. globenewswire.com - 5 months ago
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12 th , 2024 President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. globenewswire.com - 5 months ago
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript Standard BioTools Inc. (NASDAQ:LAB ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants David Holmes - IR Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Operator Good day and welcome to the Standard BioTools Inc Third Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. seekingalpha.com - 5 months ago
Standard BioTools (LAB) Reports Q3 Loss, Tops Revenue Estimates Standard BioTools (LAB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.15 per share a year ago. zacks.com - 5 months ago
Standard BioTools Reports Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024. globenewswire.com - 5 months ago
Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. globenewswire.com - 6 months ago
8. Profile Summary

Standard BioTools Inc. LAB

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 409 M
Dividend Yield 0.00%
Description Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Contact 2 Tower Place, South San Francisco, CA, 94080 https://www.fluidigm.com
IPO Date Feb. 10, 2011
Employees 814
Officers Mr. Jonathan Mickelsen Vice President & Chief Accounting Officer Mr. Sean Mackay Chief Business Officer & Senior Vice President Dr. Stephen A. Williams BS, MB, Ph.D. Chief Medical Officer Dr. Michael Egholm Ph.D. President, Chief Executive Officer & Director Ms. Elizabeth R. Jensen Chief Human Resources Officer Mr. Hanjoon Kim Chief Financial Officer